Loading...
StocksRunner logo
 
 
Biogen
0.00%
 
BIIB Biogen
Last Price
Change
 
0.00%
 
 
 

 
Sentiment
 
 

311.7

263.16

287.52

202.51

 
 
1m
3m
6m
1y
 

Summary

  Login to display Biogen (BIIB) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 

Risk Analysis

Risk Analysis

 Earnings are forecast to decrease

Risk Analysis

 Insider selling during the past 3 months

 
 

Risk Level

 
StocksRunner
 

Biogen (BIIB) has Medium Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

3.50
 

StocksRunner

 Above analyst estimates

StocksRunner

 Revenue declined YoY

StocksRunner

 Earnings decline YoY

 
 

Rating

×
 

Rating

4.53
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.22
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

3.63
 

StocksRunner

 Insider selling during the past 3 months

 

Future

×
 

Future

3.14
 

StocksRunner

 Outperform the market

StocksRunner

 Earnings are forecast to decrease

 
 

Analysts Opinion

Analysts opinion is positive but there was a setback from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
75%
79%
33%
71%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
75%
13%
Positive
Negative
62 out of 83
events present
11 out of 83
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
1 Week Ago
301.98
+1.88%
 
Options Activity
2 Weeks Ago
298.66
+0.51%
 
Buy Rating
3 Weeks Ago
310.19
-0.98%
 
Investors Selling
2 Month Ago
318.20
+1.48%
 
Options Activity
2 Month Ago
312.60
+1.07%
 
Similar Peers
Score
Closing
Price
%
Change

LEGN

Legend Biotech Corporatio

4.43

67.69

-1.77%

 

JNJ

Johnson & Johnson

3.69

160.01

-0.17%

 
 
Top Headlines

fda panel recommends full approval for biogen eisai alzheimers drug.

Fri Jun 9, 2023

Activity

us fda panel back traditional approval for eisai-biogens alzheimers drug leqembi. a panel of expert advisers on friday unanimously agreed that a late-stage clinical trial of eisai and biogens leqembi verified the benefit of the treatment for alz

Fri Jun 9, 2023

Activity

us fda panel backs approval for eisai-biogen alzheimers drug leqembi.

Fri Jun 9, 2023

Activity

fda panel weighs us approval for alzheimers drug from eisai and biogen. a panel of expert advisers on friday began their meeting to discuss whether to recommend traditional United States regulatory approval for eisai and biogens new alzheimers d

Fri Jun 9, 2023

Activity

fda panel to debate us approval for alzheimers drug from eisai and biogen. a panel of experts on friday will discuss whether to recommend traditional United States regulatory approval for eisai and biogens new alzheimers drug leqembi a move expe

Fri Jun 9, 2023

Activity

biotech stock roundup: gsk provides updates biogen to discontinue study & more. it was a busy week for the biotech sector with loads of data presentations at the 2023 american society of clinic

Thu Jun 8, 2023

Activity

biogen (biib) eisais alzheimer drug likely to get full fda nod. the fda issued briefing documents on biogen&rsquo.s biib alzheimer&rsquo.s disease (&ldquo.ad&rdquo.) drug leqembi (lecanemab) fo

Thu Jun 8, 2023

Activity

fda signals support for eisai-biogen alzheimers drug data confirms benefits for complete approval. fda peripheral and central drugs advisory committee is meeting friday (june 9) to discuss a supplemental marketing application for leqembi (lecanemab) submi

Thu Jun 8, 2023

Activity

baird reiterates biogen (biib) prior recommendation. fintel reports that on june 7 2023 baird reiterated coverage of biogen (nasdaq:biib) with a outperform recommendation.

Wed Jun 7, 2023

Potential

fda staff say eisais alzheimers drug may get full approval despite concerns. staff reviewers of the United States food and drug administration (fda) said on wednesday that eisai and biogens alzheimers drug leqembi may still be eligible for a ful

Wed Jun 7, 2023

Activity

fda staff say eisais alzheimers drug can get full approval despite safety concerns. staff reviewers of the United States food and drug administration (fda) said on wednesday that eisai and biogens alzheimers drug leqembi could still be eligible

Wed Jun 7, 2023

Activity

biogen gains on super clean fda docs on alzheimers drug ahead of adcom vote.

Wed Jun 7, 2023

Momentum

$100 invested in biogen 15 years ago would be worth this much today. biogen (nasdaq:) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 11.92%. currently biogen has a market capitaliza

Mon Jun 5, 2023

Activity

rbc capital reiterates biogen (biib) outperform recommendation. fintel reports that on june 2 2023 rbc capital reiterated coverage of biogen (nasdaq:biib) with a outperform recommendation.

Fri Jun 2, 2023

Potential

goldman sachs maintains biogen at buy with a price target of $398.00.

Thu Jun 1, 2023

Rating

piper sandler maintains biogen (biib) overweight recommendation. fintel reports that on june 1 2023 piper sandler maintained coverage of biogen (nasdaq:biib) with a overweight recommendation.

Thu Jun 1, 2023

Rating

biogen unusual options activity for may 26. someone with a lot of money to spend has taken a ish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here

Fri May 26, 2023

Momentum

heres why biogen (biib) stock is up 12.6% this year so far. biogen biib has an interesting pipeline with key assets in alzheimer&rsquo.s. biogen is exploring both early to mid-stage assets and late-stage assets to build its pipeline.

Tue May 16, 2023

Activity

biogen : canada accepts new drug submission for lecanemab as treatment for early alzheimers disease. (rttnews) - eisai co. ltd. and biogen inc. (biib) said that health canada has accepted a new drug submission or nds for lecanemab (brand name in

Tue May 16, 2023

Activity

3 reasons to buy biogen stock (and 1 to sell). biogen (nasdaq: biib) has been a polarizing stock to own over the past few years. aduhelms accelerated approval sent the stock soaring a few years ago but after controversy surrounding its approval

Fri May 12, 2023

Momentum
Potential

argus research maintains biogen (biib) buy recommendation. fintel reports that on may 11 2023 argus research maintained coverage of biogen (nasdaq:biib) with a buy recommendation.

Thu May 11, 2023

Rating

(biib) - analyzing biogens short interest. ) short percent of float has risen 7.59% since its last report. the company recently reported that it has

Wed May 10, 2023

Activity

biogen unusual options activity. someone with a lot of money to spend has taken a bearish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here at benz

Fri May 5, 2023

Activity
Activity
Momentum
Potential

b of a securities maintains biogen (biib) neutral recommendation. fintel reports that on may 4 2023 b of a securities maintained coverage of biogen (nasdaq:biib) with a neutral recommendation.

Thu May 4, 2023

Rating

$1000 invested in biogen 15 years ago would be worth this much today. biogen (nasdaq:) has outperformed the market over the past 15 years by 4.42% on an annualized basis producing an average annual return of 11.92%. currently biogen has a market capitaliz

Wed May 3, 2023

Activity

notable wednesday option activity: biib gpre chk. looking at options trading activity among components of the russell 3000 index there is noteworthy activity today in biogen inc (symbol: biib) where a total volume of 5602 contracts has been

Wed May 3, 2023

Momentum

biogen unusual options activity for may 03. a whale with a lot of money to spend has taken a noticeably bearish stance on looking at options history for biogen (nasdaq:) we detected 11 strange trades. if we consider the specifics of each trade it is ac

Wed May 3, 2023

Activity
Activity
Momentum
Potential

biogen recent insider activity. ) reported a large insider sell on may 2 according to a new sec filing. United States securities and exchange commission on tues

Wed May 3, 2023

Activity

biogen up as guggenheim upgrades citing full approval for leqembi.

Mon May 1, 2023

Activity
Rating

guggenheim upgrades biogen (biib). fintel reports that on may 1 2023 guggenheim upgraded their outlook for biogen (nasdaq:biib) from neutral to buy .

Mon May 1, 2023

Rating

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily BIIB alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

BIIB Biogen

Last Price
Change
0.00%
 

Summary

  Login to display Biogen (BIIB) recommendation from the last 90 days from financial news and social media.

 
 
311.7
263.16
287.52
202.51
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Risk Analysis

Risk Analysis

 Earnings are forecast to decrease

Risk Analysis

 Insider selling during the past 3 months

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
79%
33%
71%
On Track
On Track
On Track
 
75%
13%
Positive
Negative
62 out of 83
events present
11 out of 83
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

3.50
 

StocksRunner

 Above analyst estimates

StocksRunner

 Revenue declined YoY

StocksRunner

 Earnings decline YoY

 
 

Rating

×
 

Rating

4.53
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.22
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

3.63
 

StocksRunner

 Insider selling during the past 3 months

 

Future

×
 

Future

3.14
 

StocksRunner

 Outperform the market

StocksRunner

 Earnings are forecast to decrease

 
 

Analysts Opinion

Analysts opinion is positive but there was a setback from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Biogen (BIIB) has Medium Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
1 Week Ago
301.98
+1.88%
 
Options Activity
2 Weeks Ago
298.66
+0.51%
 
Buy Rating
3 Weeks Ago
310.19
-0.98%
 
Investors Selling
2 Month Ago
318.20
+1.48%
 
Options Activity
2 Month Ago
312.60
+1.07%
 
 
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily BIIB Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines